A PHASE I STUDY OF CLOFARABINE PLUS HIGH DOSE MELPHALAN AS A CONDITIONING REGIMEN FOR ALLOGENEIC TRANSPLANTATION

被引：0
|
作者：
Kirschbaum, M. H. [1 ]
Stein, A. S. [1 ]
Nakamura, R. [1 ]
Auayporn, N. [1 ]
Popplewell, L. [1 ]
Delioukina, M. [1 ]
Chen, R. [1 ]
Snyder, D. [1 ]
Conrad, J. [1 ]
Frankel, P. [1 ]
Forman, S. J. [1 ]
机构：
[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2010年 / 16卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2009.12.367
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
323
引用
收藏
页码：S278 / S278
页数：1
相关论文
共 50 条
  • [21] Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long Term Study Results
    Kebriaei, Partow
    Bassett, Roland
    Lyons, Genevieve
    Valdez, Ben
    Ledesma, Celina
    Rondon, Gabriela
    Oran, Betul
    Ciurea, Stefan
    Alousi, Amin
    Popat, Uday
    Patel, Krina
    Ahmed, Sairah
    Olson, Amanda
    Bashir, Qaiser
    Shah, Nina
    Jones, Roy
    Marin, David
    Rezvani, Katayoun
    Nieto, Yago
    Khouri, Issa
    Qazilbash, Muzaffar
    Hosing, Chitra
    Shpall, Elizabeth
    Champlin, Richard E.
    Andersson, Borje S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (02) : 285 - 292
  • [22] Clofarabine and Total Body Irradiation as a Conditioning Regimen for Allogeneic Stem Cell Transplantation in High-Risk Acute Leukemia
    Atoui, Ali
    Dulery, Remy
    Terro, Khodr
    Abou Dalle, Iman
    Bazarbachi, Ali
    Mohty, Mohamad
    El Cheikh, Jean
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S432 - S432
  • [23] A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    Noa Biran
    Scott D. Rowley
    David H. Vesole
    Shijia Zhang
    Michele L. Donato
    Alan P. Skarbnik
    Joshua Richter
    Andrew Pecora
    David S. Siegel
    Bone Marrow Transplantation, 2019, 54 : 1881 - 1891
  • [24] A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    Biran, Noa
    Rowley, Scott D.
    Vesole, David H.
    Zhang, Shijia
    Donato, Michele L.
    Skarbnik, Alan P.
    Richter, Joshua
    Pecora, Andrew
    Siegel, David S.
    BONE MARROW TRANSPLANTATION, 2019, 54 (11) : 1881 - 1891
  • [25] Fludarabine/full dose i.v. busulfan conditioning regimen in allogeneic PBSC transplantation for high risk patients
    Chunduri, S.
    Dobogai, L. C.
    Peace, D.
    Saunthararajah, Y.
    Quigley, J.
    Chen, Y. -H.
    Boccuni, P.
    Hoffman, R.
    Mahmud, N.
    Beri, R.
    Hurter, E.
    Rondelli, D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 84 - 84
  • [26] Phase I Trial of High-Dose Clofarabine and Busulfan as a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia
    Farag, Sherif
    Wood, Lisa L.
    Schwartz, Jennifer E.
    Srivastava, Shivani
    Nelson, Robert P., Jr.
    Robertson, Michael
    Abonour, Rafat
    Sayar, Hamid
    Cripe, Larry D.
    BLOOD, 2009, 114 (22) : 86 - 86
  • [27] Bortezomib after high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with multiple myeloma: A comparison with the historical conditioning regimen with melphalan alone
    Ferini, G. A.
    Arbelbide, J. A.
    Basquiera, A. L.
    Nucifora, E.
    Schutz, N.
    Otero, V.
    Fantl, D.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S461 - S462
  • [28] Busulfan and melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Jin Seok
    Min, Chang-Ki
    Kim, Kihyun
    Choi, Yunsuk
    Eom, Hyeon-Seok
    Joo, Young Don
    Kim, Sung-Hyun
    Kwak, Jae-Yong
    Kang, Hye Jin
    Lee, Jae Hoon
    Lee, Ho Sup
    Mun, Yeung-Chul
    Moon, Joon Ho
    Sohn, Sang Kyun
    Park, Seong Kyu
    Park, Yong
    Shin, Ho-Jin
    Yoon, Sung-Soo
    BONE MARROW TRANSPLANTATION, 2018, 53 : 262 - 263
  • [29] High dose idarubicine, busulphan and melphalan conditioning regimen for lymphoproliferative disorders
    Trasarti, S
    Meloni, G
    Capria, S
    Bongarzoni, V
    Ferrazza, G
    Iodice, F
    Proia, A
    Trisolini, SM
    Mandelli, F
    BONE MARROW TRANSPLANTATION, 1998, 21 : S100 - S100
  • [30] High dose Melphalan/Thiotepa conditioning regimen for resistant lymphoma.
    Kirschbaum, MH
    Gur, O
    Nadav, L
    Naparstek, E
    BLOOD, 2002, 100 (11) : 477B - 477B
12345